BD Announces CE Marking of a New Molecular Test to Diagnose Patients with Clostridium difficile Infections
News Jul 07, 2008
BD Diagnostics has announced the CE marking of the BD GeneOhm™ Cdiff molecular assay for the rapid diagnosis of patients with Clostridium difficile infection (CDI). It is said to be the first CDI diagnostic test that can offer sensitivity, simplicity and speed in one test procedure. BD has also submitted this assay to the U.S. Food and Drug Administration for clearance.
CE marked under the European In Vitro Diagnostics Directive for the identification of toxigenic Clostridium difficile directly from stool specimens, the BD GeneOhm Cdiff assay targets the toxin B gene, found in toxigenic Clostriduim difficile strains. It is the only CDI diagnostic test that combines high assay sensitivity with a turnaround time of less than two hours, facilitating earlier appropriate treatment of patients suffering from CDI and earlier implementation of infection control interventions to prevent transmission of Clostridium difficile to other patients.
Until now, rapid diagnosis of CDI has been difficult since traditional methods consist of immunoassays, which lack sufficient sensitivity, and traditional "gold standard" tissue culture cytotoxicity methods, which are difficult to perform and require several days to yield results.
"The BD GeneOhm Cdiff assay provides a simple and rapid stool test with excellent sensitivity and specificity that allows same-day identification of toxigenic Clostridium difficile," said Thomas Davis, M.D., Ph.D., Professor, Pathology and Laboratory Medicine, Clarian Pathology Laboratory.
"This test should improve patient care because it effectively eliminates the need for multiple screening and confirmatory assays, speeds up reporting and helps avoid unnecessary antibiotic use."
"CDI poses a significant challenge for healthcare facilities around the world," said Jamie Condie, Vice President and General Manager, BD Diagnostics - GeneOhm.
"The introduction of the BD GeneOhm Cdiff assay demonstrates BD's ongoing commitment to develop a broad range of products that can help prevent healthcare-associated infections (HAIs). BD provides molecular tests for key pathogens associated with HAIs, including methicillin-resistant Staphylococcus aureus (MRSA), methicillin-susceptible Staphylococcus aureus, vancomycin-resistant Enterococci, and now Clostridium difficile."
In the United Kingdom, Clostridium difficile infections have risen 40 percent in the last three years, infecting eight times as many patients as MRSA and killing twice as many. In the United States annually, an estimated 500,000 people are hospitalized and more than 28,000 die from CDI.
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE
3-D Tissue Model of Developing Heart Could Aid Drug Safety Testing for Pregnant WomenNews
Parents and doctors often have to consider the mother's health as well as the potential risk regarding how medication could affect their baby. Researchers have developed a process to make a 3D tissue model that could mimic early stage human heart development, which could aid drug safety testing and help determine a drug's effects on fetal development.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018